Belfast Health & Social Care Trust, Belfast, United Kingdom.
Belfast Health & Social Care Trust, Belfast, United Kingdom.
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1448-1457. doi: 10.1016/j.jcin.2020.03.032.
The aim of this study was to assess angiographic, imaging, and clinical outcomes following chronic total occlusion (CTO) percutaneous coronary intervention (PCI) with dissection and re-entry techniques (DART) and subintimal (SI) stenting compared with intimal techniques.
Reliable procedural success and safety in CTO PCI require the use of DART to treat the most complex patients. Potential concerns regarding the durability of DART with SI stenting still need to be addressed.
This was a prospective, multicenter, single-arm trial of patients with appropriate indications for CTO PCI.
Successful CTO PCI was performed in 210 of 231 patients (91% success). At 1 year, the primary endpoint of target vessel failure (cardiac death, myocardial infarction related to the target vessel, or any ischemia-driven revascularization) occurred in 5.7% of patients, meeting the pre-set performance goal. Major adverse cardiovascular events (all-cause mortality, myocardial infarction, or target vessel revascularization) occurred in 10% at 1 year and 17% by 2 years and was not influenced by DART. Quality-of-life measures significantly improved from baseline to 12 months. There was no difference in intravascular healing assessed using optical coherence tomography at 12 months for patients treated with DART and SI stenting compared with intimal strategies.
Contemporary CTO PCI is associated with medium-term clinical outcomes comparable with those achieved in other complex PCI cohorts and significant improvements in quality of life. The use of DART with SI stenting does not adversely affect intravascular healing at 12 months or medium-term major adverse cardiovascular events. (Consistent CTO Trial; NCT02227771).
本研究旨在评估慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)中应用夹层和再进入技术(DART)与内膜下(SI)支架置入术与内膜技术相比的血管造影、影像学和临床结局。
在 CTO PCI 中,可靠的手术成功率和安全性需要使用 DART 来治疗最复杂的患者。对于 DART 联合 SI 支架置入术的耐久性,仍需要解决一些潜在的关注问题。
这是一项前瞻性、多中心、单臂试验,纳入了适合 CTO PCI 的患者。
231 例患者中有 210 例(91%)成功进行了 CTO PCI。在 1 年时,目标血管失败的主要终点(心脏死亡、与目标血管相关的心肌梗死或任何缺血驱动的血运重建)在 5.7%的患者中发生,达到了预先设定的性能目标。主要不良心血管事件(全因死亡率、心肌梗死或靶血管血运重建)在 1 年时为 10%,在 2 年时为 17%,且不受 DART 的影响。生活质量指标从基线到 12 个月显著改善。在 12 个月时,使用光学相干断层扫描评估血管内愈合,与内膜策略相比,接受 DART 和 SI 支架置入术的患者没有差异。
当代 CTO PCI 与其他复杂 PCI 队列的中期临床结局相当,并显著改善了生活质量。在 12 个月或中期内,DART 联合 SI 支架置入术不会对血管内愈合或主要不良心血管事件产生不利影响。(一致性 CTO 试验;NCT02227771)。